Analyst firms · Oppenheimer · ALNY

Oppenheimer ALNY price target and rating history

Alnylam Pharmaceuticals Inc. (ALNY) · Health Care

Oppenheimer rates Alnylam Pharmaceuticals Inc. (ALNY) Outperform with a $500 price target, as of its latest action on Jan 7, 2026. It has published 4 rating actions on ALNY since November 2021, including 2 upgrades and 1 downgrade. Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Oppenheimer's $500 is 54% above that.

Current rating
Outperform
Price target
$500
Median target, all firms
$324
Actions on ALNY
4

Oppenheimer price target on ALNY

$500$350$20020222023202420252026
Oppenheimer price target on ALNY, each point a stated target, November 2021 to January 2026.

Every Oppenheimer rating on ALNY

How other firms rate ALNY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Truist SecuritiesHold$225Nov 2, 2026
BernsteinMkt Perform$199Oct 30, 2026
Raymond JamesOutperform$315Oct 30, 2026
StifelHold$225Oct 29, 2026
UBSBuy$354Oct 15, 2026
BMO Capital MarketsOutperform$318Aug 19, 2026
CitigroupBuy$380May 19, 2026
JefferiesHold$330Mar 16, 2026
BarclaysOverweight$527Jan 28, 2026
OppenheimerOutperform$500Jan 7, 2026

Questions about Oppenheimer and ALNY

What is Oppenheimer's price target for ALNY?
Oppenheimer's latest stated price target for Alnylam Pharmaceuticals Inc. (ALNY) is $500, from its action on Jan 7, 2026.
What is Oppenheimer's rating on ALNY?
Oppenheimer rates ALNY Outperform, a bullish rating, as of Jan 7, 2026.
When did Oppenheimer last change its view on ALNY?
On Jan 7, 2026, Oppenheimer resumes coverage at Outperform, price target $500.
How does Oppenheimer's ALNY target compare with other analysts?
Across 10 firms with a ALNY price target in the last 12 months, the median target is $324. Oppenheimer's $500 is 54% above that.

More ALNY rating histories

All Oppenheimer ratingsALNY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.